Repository logo
 
Publication

Segmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).

dc.contributor.authorSchleiermacher, G.
dc.contributor.authorMichon, J.
dc.contributor.authorRibeiro, A.
dc.contributor.authorPierron, G.
dc.contributor.authorMosseri, V.
dc.contributor.authorRubie, H.
dc.contributor.authorMunzer, C.
dc.contributor.authorBénard, J.
dc.contributor.authorAuger, N.
dc.contributor.authorCombaret, V.
dc.contributor.authorJanoueix-Lerosey, I.
dc.contributor.authorPearson, A.
dc.contributor.authorTweddle, D.A.
dc.contributor.authorBown, N.
dc.contributor.authorGerrard, M.
dc.contributor.authorWheeler, K.
dc.contributor.authorNoguera, R.
dc.contributor.authorVillamon, E.
dc.contributor.authorCañete, A.
dc.contributor.authorCastel, V.
dc.contributor.authorMarques, B.
dc.contributor.authorde Lacerda, A.
dc.contributor.authorTonini, G.P.
dc.contributor.authorMazzocco, K.
dc.contributor.authorDefferrari, R.
dc.contributor.authorde Bernardi, B.
dc.contributor.authordi Cataldo, A.
dc.contributor.authorvan Roy, N.
dc.contributor.authorBrichard, B.
dc.contributor.authorLadenstein, R.
dc.contributor.authorAmbros, I.
dc.contributor.authorAmbros, P.
dc.contributor.authorBeiske, K.
dc.contributor.authorDelattre, O.
dc.contributor.authorCouturier, J.
dc.date.accessioned2012-03-15T12:49:07Z
dc.date.available2012-03-15T12:49:07Z
dc.date.issued2011-12
dc.description.abstractBACKGROUND: In neuroblastoma (NB), the presence of segmental chromosome alterations (SCAs) is associated with a higher risk of relapse. METHODS: In order to analyse the role of SCAs in infants with localised unresectable/disseminated NB without MYCN amplification, we have performed an array CGH analysis of tumours from infants enrolled in the prospective European INES trials. RESULTS: Tumour samples from 218 out of 300 enroled patients could be analysed. Segmental chromosome alterations were observed in 11%, 20% and 59% of infants enroled in trials INES99.1 (localised unresectable NB), INES99.2 (stage 4s) and INES99.3 (stage 4) (P<0.0001). Progression-free survival was poorer in patients whose tumours harboured SCA, in the whole population and in trials INES99.1 and INES99.2, in the absence of clinical symptoms (log-rank test, P=0.0001, P=0.04 and P=0.0003, respectively). In multivariate analysis, a SCA genomic profile was the strongest predictor of poorer progression-free survival. CONCLUSION: In infants with stage 4s MYCN-non-amplified NB, a SCA genomic profile identifies patients who will require upfront treatment even in the absence of other clinical indication for therapy, whereas in infants with localised unresectable NB, a genomic profile characterised by the absence of SCA identifies patients in whom treatment reduction might be possible. These findings will be implemented in a future international trial.por
dc.identifier.citationBr J Cancer. 2011 Dec 6;105(12):1940-8. Epub 2011 Nov 10por
dc.identifier.issn0007-0920
dc.identifier.otherdoi: 10.1038/bjc.2011.472.
dc.identifier.urihttp://hdl.handle.net/10400.18/794
dc.language.isoengpor
dc.peerreviewedyespor
dc.publisherNature Publishing Grouppor
dc.relation.publisherversionhttp://www.nature.com/bjc/journal/v105/n12/full/bjc2011472a.htmlpor
dc.subjectDoenças Genéticaspor
dc.subjectNeuroblastomapor
dc.subjectSegmental Chromosome Alterationspor
dc.subjectHigh Riskpor
dc.titleSegmental chromosomal alterations lead to a higher risk of relapse in infants with MYCN-non-amplified localised unresectable/disseminated neuroblastoma (a SIOPEN collaborative study).por
dc.typejournal article
dspace.entity.typePublication
oaire.citation.endPage1948por
oaire.citation.startPage1940por
oaire.citation.titleBritish Journal of Cancerpor
rcaap.rightsrestrictedAccesspor
rcaap.typearticlepor

Files

Original bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
SCA_BJC_2011.pdf
Size:
520.37 KB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
No Thumbnail Available
Name:
license.txt
Size:
1.71 KB
Format:
Item-specific license agreed upon to submission
Description: